Document Detail


Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
MedLine Citation:
PMID:  23046156     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapeutic strategies designed to treat HIV infection with combinations of antiviral drugs have proven to be the best approach for slowing the progression to AIDS. Despite the great success of highly active antiretroviral therapy (HAART), drug resistance and toxicity issues still remain a concern for some individuals. Therefore, alternative therapeutic strategies need to be developed to overcome these limitations. Nucleic acid-based therapeutics have been considered as an alternative to the currently used antivirals. In this regard, RNA interference (RNAi) can function as a gene-specific therapeutic option for controlling HIV-1 replication. Another type of therapeutic nucleic acid - aptamers - shows promise as a new and potent class of anti-HIV agent and can additionally function as a cell-type-specific delivery vehicle for targeted RNAi. The combined use of small interfering RNA (siRNAs) and aptamers could effectively block viral replication and prevent the emergence of resistant variants. In this review, we recapitulate recent progress and the therapeutic potential of aptamer-siRNA conjugates in the treatment of HIV infection.
Authors:
Jiehua Zhou; John J Rossi
Related Documents :
24499926 - Is there life after debi? examining health behavior maintenance in the diffusion of eff...
23931166 - Personal perspectives.
24937136 - Hiv among people who inject drugs in the middle east and north africa: systematic revie...
23492996 - Global evidence directing regional preventive strategies in southeast asia for fighting...
11416716 - Initiating co-trimoxazole prophylaxis in hiv-infected patients in africa: an evaluation...
1452696 - Detection of serum candida antigens by enzyme-linked immunosorbent assay and a latex ag...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  26     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-10-30     Completed Date:  2013-04-01     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  393-400     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aptamers, Nucleotide / genetics*
HIV Infections / drug therapy*,  virology
HIV-1 / drug effects*,  genetics
Humans
RNA, Small Interfering / administration & dosage*,  genetics
SELEX Aptamer Technique
Virus Replication / drug effects,  genetics
Grant Support
ID/Acronym/Agency:
AI29329/AI/NIAID NIH HHS; AI42552/AI/NIAID NIH HHS; HL07470/HL/NHLBI NIH HHS; R01 AI029329/AI/NIAID NIH HHS; R01 AI042552/AI/NIAID NIH HHS; R01 HL074704/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Aptamers, Nucleotide; 0/RNA, Small Interfering
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surface Modification and Reinforcement of Silica Aerogels Using Polyhedral Oligomeric Silsesquioxane...
Next Document:  Epidermotropic secondary cutaneous involvement by relapsed angioimmunoblastic T-cell lymphoma mimick...